PDF DatasheetHuman, Monkey, Baboon, Cat, Rabbit, Ferret, Mouse (-), and Rat (-) Anti-NGF-Receptor / CD271 Antibody Product Attributes
NGF-Receptor / CD271 Previously Observed Antibody Staining Patterns
Observed Subcellular, Organelle Specific Staining Data:
Anti-NGFR antibody staining is expected to be primarily localized to the nucleoplasm and plasma membrane.
Observed Antibody Staining Data By Tissue Type:
Variations in NGF-Receptor / CD271 antibody staining intensity in immunohistochemistry on tissue sections are present across different anatomical locations. An intense signal was observed in peripheral nerve/ganglion in colon. More moderate antibody staining intensity was present in peripheral nerve/ganglion in colon. Low, but measureable presence of NGF-Receptor / CD271 could be seen inrespiratory epithelial cells in the bronchus, squamous epithelial cells in the cervix, uterine and esophagus, glandular cells in the gallbladder, respiratory epithelial cells in the nasopharynx, squamous epithelial cells in the oral mucosa, keratinocytes in skin and squamous epithelial cells in the tonsil. We were unable to detect NGF-Receptor / CD271 in other tissues. Disease states, inflammation, and other physiological changes can have a substantial impact on antibody staining patterns. These measurements were all taken in tissues deemed normal or from patients without known disease.
Observed Antibody Staining Data By Tissue Disease Status:
Tissues from cancer patients, for instance, have their own distinct pattern of NGF-Receptor / CD271 expression as measured by anti-NGF-Receptor / CD271 antibody immunohistochemical staining. The average level of expression by tumor is summarized in the table below. The variability row represents patient to patient variability in IHC staining.
| Sample Type | breast cancer | carcinoid | cervical cancer | colorectal cancer | endometrial cancer | glioma | head and neck cancer | liver cancer | lung cancer | lymphoma | melanoma | ovarian cancer | pancreatic cancer | prostate cancer | renal cancer | skin cancer | stomach cancer | testicular cancer | thyroid cancer | urothelial cancer |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Signal Intensity | – | – | – | – | – | + | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| NGFR Variability | + | ++ | + | + | + | ++ | ++ | + | + | ++ | + | + | + | + | + | ++ | + | + | + | ++ |
| NGF-Receptor / CD271 General Information | |
|---|---|
| Alternate Names | |
| low-affinity nerve growth factor receptor, nerve growth factor receptor, TNFR superfamily, member 16, LNGFR, p75 neurotrophin receptor, p75 NTR, p75 NGF receptor | |
| Molecular Weight | |
| 75kDa | |
| Chromosomal Location | |
| 17q21-22 | |
| Curated Database and Bioinformatic Data | |
| Gene Symbol | NGFR |
| Entrez Gene ID | 4804 |
| Ensemble Gene ID | ENSG00000064300 |
| RefSeq Protein Accession(s) | NP_002498 |
| RefSeq mRNA Accession(s) | NM_002507 |
| RefSeq Genomic Accession(s) | NC_018928, NC_000017 |
| UniProt ID(s) | P08138 |
| UniGene ID(s) | P08138 |
| HGNC ID(s) | 7809 |
| Cosmic ID(s) | NGFR |
| KEGG Gene ID(s) | hsa:4804 |
| PharmGKB ID(s) | PA31615 |
| General Description of NGF-Receptor / CD271. | |
| It recognizes a glycoprotein of 75kDa, identified as low affinity Nerve Growth Factor (NGF) Receptor (p75NGFR) or Neurotrophin Receptor (p75NTR). Its epitope spans in aa 1-160 of extracellular domain of NGFR/NTR. NGF-receptor contains an extracellular domain containing four 40-amino acid repeats with 6 cysteine residues at conserved positions followed by a serine/threonine-rich region, a single transmembrane domain,, a 155-amino acid cytoplasmic domain. The cysteine-rich region contains the nerve growth factor binding domain. NGF is important for the development, differentiation,, survival of variety of neuronal, non-neuronal cells. Its action is mediated by binding two distinct receptors, the high affinity p140, low affinity p75. | |
There are no reviews yet.